The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global
pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are …

Critically ill patients often acquire neuropathy and/or myopathy labeled ICU-acquired
weakness. The current insights into incidence, pathophysiology, diagnostic tools, risk …

As of August 2022, there have been over 572 million confirmed cases of COVID-19 (9). The
pandemic has thus far claimed approximately 6.39 million lives (9). Vaccination is having a …

Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …

Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

Objectives To develop evidence-based recommendations for clinicians caring for children
(including infants, school-aged children, and adolescents) with septic shock and other …

Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …

Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …

Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …

Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …